[Cannabidiol in epilepsy. National versus international products comparison]
Argento F, García Martí S, Alfie V, Perelli L, Mejía J, Ciapponi A, Augustovski F, Pichón-Riviere A, Alcaraz A, Bardach A
Record ID 32018012836
Spanish
Original Title:
Cannabidiol en epilepsia. Comparación de productos nacionales versus internacionales
Authors' recommendations:
"Conclusions
No studies comparing the efficacy, safety or bioequivalence of cannabidiol of Argentinian producers versus international products were found. Therefore, it is not possible to evaluate the comparative efficacy between national and international products.
However, the active ingredient concentration, as well as the route of administration of national brands is similar to that of the leading international brand approved by regulatory agencies of the United States of America (FDA) and the European Union (EMA). National products Convupidiol® and Kanbis® are the only marketed products in Argentina."
Details
Project Status:
Completed
URL for project:
https://ets.iecs.org.ar/publication/2109
Year Published:
2023
URL for published report:
https://ets.iecs.org.ar/publication/2109
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Cannabidiol
- Anti-Anxiety Agents
- Quality Control
- Pharmaceutical Preparations
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.